Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na⁺) through a cell’s plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na⁺ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.
**Sodium Channel Inhibitors & Modulators**

**(-)-Sparteine sulfate pentahydrate**  
((-)-Sparteine sulfate salt; Lupinidine sulfate pentahydrate)  
Cat. No.: HY-B1304

**Bioactivity:** (-)-Sparteine sulfate pentahydrate is a class 1a antiarrhythmic agent and a sodium channel blocker

**Purity:** 98.0%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 50 mg

**A-803467**  
Cat. No.: HY-11079

**Bioactivity:** A-803467 is a selective Nav1.8 sodium channel blocker with an IC50 of 8 nM; over 100-fold more selective vs. human Nav1.2, 1.3, 1.5 and 1.7.

**Purity:** 97.51%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg

**Ajmaline**  
(Cardiohythmine; (+)-Ajmaline)  
Cat. No.: HY-B1167

**Bioactivity:** Ajmaline is an alkaloid that is class 1a antiarrhythmic agent

**Purity:** 99.31%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg

**AM-2099**  
Cat. No.: HY-100727

**Bioactivity:** AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC50 of 0.16 μM for human Nav1.7.

**Purity:** 98.0%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**Amiloride**  
(MK-870)  
Cat. No.: HY-80285

**Bioactivity:** Amiloride is a relatively selective inhibitor of the epithelial <b>sodium channel (ENaC), used in the management of hypertension and congestive heart failure.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 100 mg

**Amiloride hydrochloride**  
(MK-870 hydrochloride)  
Cat. No.: HY-80285A

**Bioactivity:** Amiloride (hydrochloride) is a relatively selective inhibitor of the epithelial sodium channel (ENaC), used in the management of hypertension and congestive heart failure.

**Purity:** 98.0%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg

**Amiloride hydrochloride dihydrate**  
(MK-870 hydrochloride dihydrate)  
Cat. No.: HY-80285B

**Bioactivity:** Amiloride hydrochloride dihydrate is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA).

**Purity:** 98.56%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 100 mg

**Amitriptyline hydrochloride**  
Cat. No.: HY-80527A

**Bioactivity:** Amitriptyline Hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA).

**Purity:** 99.64%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 1 g, 5 g

**Benzamil hydrochloride**  
(Benzyamiloride hydrochloride)  
Cat. No.: HY-B1546A

**Bioactivity:** Benzamil hydrochloride is a specific blocker of sodium channel (ENaC).

**Purity:** 99.46%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Benzocaine**  
Cat. No.: HY-Y0258

**Bioactivity:** Benzocaine is a common receptor with all other local anesthetics (LAs) in the voltage-gated Na+ channel. Exerts an indirect action on the membrane permeability to calcium. Key steps of the Ca-ATPase enzymatic cycle.

**Purity:** 99.98%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 5 g, 10 g

---

Tel: 609-228-6898  Fax: 609-228-5909  Email: sales@medchemexpress.com
<table>
<thead>
<tr>
<th><strong>Bulleyaconitine A</strong></th>
<th><strong>Cat. No.: HY-N0239</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Bulleyaconitine A is an analgesic and antiinflammatory drug isolated from Aconitum plants; has several potential targets, including voltage-gated Na+ channels.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mg, 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **Carbamazepine** | **(CBZ; NSC 169864) | **Cat. No.: HY-B0246** |
|-------------------|---------------------|
| **Bioactivity:** Carbamazepine, a sodium channel blocker, is an anticonvulsant drug. |
| **Purity:** 99.35% |
| **Clinical Data:** Launched |
| **Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg |

| **Cariporide** | **(HOE-642)** | **Cat. No.: HY-19693** |
|----------------|----------------|
| **Bioactivity:** Cariporide (HOE-642) is a selective Na⁺/H⁺ exchange inhibitor. |
| **Purity:** 98.57% |
| **Clinical Data:** No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **Cenobamate** | **(YKP3089)** | **Cat. No.: HY-17607** |
|----------------|----------------|
| **Bioactivity:** Cenobamate, a sodium channel blocker, enhances GABAergic transmission and has the potential to be a versatile CNS drug. |
| **Purity:** 99.50% |
| **Clinical Data:** No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

<table>
<thead>
<tr>
<th><strong>Chlorpromazine D6 hydrochloride</strong></th>
<th><strong>Cat. No.: HY-B0407AS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Chlorpromazine D6 hydrochloride is the deuterium labeled Chlorpromazine. Chlorpromazine is an inhibitor of dopamine receptor, 5-HT receptor, potassium channel, sodium channel.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1 mg, 5 mg, 10 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Chlorpromazine hydrochloride</strong></th>
<th><strong>Cat. No.: HY-B0407A</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Chlorpromazine Hydrochloride is an antagonist of the dopamine D₂ receptors, 5-HT₂A receptors, &lt;b&gt;potassium channel, sodium channel&lt;/b&gt;, with Ki values of 363 nM and 8.3 nM for dopamine D₂ receptor and serotonin 5-HT₂A receptor, respectively.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.83%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Launched</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1 g, 5 g</td>
<td></td>
</tr>
</tbody>
</table>

| **CNV1014802** | **(GSK-1014802; Raxatrigine) | **Cat. No.: HY-12796** |
|----------------|-----------------------------|
| **Bioactivity:** CNV1014802(GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor. |
| **Purity:** 99.47% |
| **Clinical Data:** Phase 2 |
| **Size:** 5 mg, 10 mg, 50 mg, 100 mg |

| **CNV1014802 hydrochloride** | **(GSK-1014802 hydrochloride; Raxatrigine hydrochloride) | **Cat. No.: HY-12796A** |
|-----------------------------|-----------------------------------------------------------|
| **Bioactivity:** CNV1014802(GSK-1014802) HCl is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor. |
| **Purity:** 98.69% |
| **Clinical Data:** Phase 2 |
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **Dibucaine** | **(Cinchocaine)** | **Cat. No.: HY-80552** |
|---------------|-------------------|
| **Bioactivity:** Dibucaine is a local anesthetic of the amide type now generally used for surface anesthesia. |
| **Purity:** 99.81% |
| **Clinical Data:** Launched |
| **Size:** 10mM x 1mL in DMSO, 5 g, 10 g |

| **Dibucaine hydrochloride** | **(Cinchocaine hydrochloride) | **Cat. No.: HY-80552A** |
|-----------------------------|-------------------------------|
| **Bioactivity:** Dibucaine Hydrochloride is a local anesthetic of the amide type now generally used for surface anesthesia. |
| **Purity:** 99.67% |
| **Clinical Data:** No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 5 g, 10 g |
| **Dyclonine hydrochloride**  
(Dyclocaine hydrochloride) | **EIPA**  
(L93754; MH 12-43; Ethylisopropylamiloride) |
|---------------------------|---------------------------------------------|
| **Bioactivity:** Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge.  
**Purity:** 99.72%  
**Clinical Data:** Launched  
**Size:** 10mM x 1ml in DMSO, 5g, 10g | **Bioactivity:** EIPA is a TRPP3 channel inhibitor with an $IC_{50}$/inhib of 10.5 μM. EIPA also inhibits Na$^+$/H$^+$ exchanger (NHE) and macropinocytosis.  
**Purity:** 99.73%  
**Clinical Data:** No Development Reported  
**Size:** 5mg, 10mg |

| **Eleclazine hydrochloride**  
(GS 6615 hydrochloride) | **Eniporide hydrochloride**  
(EMD-96785 hydrochloride) |
|--------------------------|----------------------------|
| **Bioactivity:** Eleclazine hydrochloride is a novel Na$^+$ current inhibitor with an IC$\text{50}$ value of 0.7μM.  
**Purity:** 99.47%  
**Clinical Data:** Phase 3  
**Size:** 10mM x 1ml in DMSO, 1mg, 5mg, 10mg, 25mg, 50mg, 100mg | **Bioactivity:** Eniporide hydrochloride (EMD-96785 hydrochloride) is a potent Na$^+$ /H$^+$ exchange inhibitor.  
**Purity:** 99.31%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1ml in DMSO, 5mg, 10mg, 25mg, 50mg |

| **Eslicarbazepine acetate**  
(BIA 2-093) | **Flecainide**  
|-----------------|-----------------------------|
| **Bioactivity:** Eslicarbazepine acetate (BIA 2-093) is an antiepileptic drug.  
**Purity:** 99.48%  
**Clinical Data:** Launched  
**Size:** 10mM x 1ml in DMSO, 10mg, 50mg, 100mg, 500mg | **Bioactivity:** Flecainide(Tambocor) is a class IC antiarrhythmic drug especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.  
**Purity:** 99.65%  
**Clinical Data:** Launched  
**Size:** 10mM x 1ml in DMSO, 10mg, 50mg, 100mg |

| **FR183998 free base** | **Funapide**  
(XEN402) |
|-------------------------|------------------|
| **Bioactivity:** FR183998 free base is a potent Na$^+$/H$^+$-exchanger inhibitor, with $IC_{50}$ of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pH change in rat lymphocytes and rat and human platelets, respectively.  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1mg, 5mg, 10mg | **Bioactivity:** Funapide is a potent Sodium Channel Nav1.7 inhibitor.  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 250mg, 500mg |

| **Ginsenoside Rg3**  
(20(S)-Ginsenoside-Rg3; Rg3; 5-Ginsenoside Rg3) | **GS967**  
(GS-458967) |
|---------------------------------------------|------------------|
| **Bioactivity:** Ginsenoside Rg3 is the main component of Red ginseng. Ginsenoside Rg3 inhibits Na$^+$ and Kv1.4 channel with $IC_{50}$ of 32.2±4.5 and 32.6±2.2μM, respectively. Ginsenoside Rg3 also inhibits Aβ, NF-κB activity, and d COX-2 expression.  
**Purity:** 98.0%  
**Clinical Data:** Phase 2  
**Size:** 10mM x 1ml in DMSO, 10mg, 50mg, 100mg | **Bioactivity:** GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late $I_{Na}$) with $IC_{50}$ values of 0.13 and 0.21 μM for ventricular myocytes and d isolated hearts, respectively.  
**Purity:** 99.96%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1ml in DMSO, 5mg, 10mg, 50mg, 100mg, 200mg |
ICA-121431
Cat. No.: HY-16787

Bioactivity: ICA-121431 is a nanomolar potent small molecule Nav1.7 channel inhibitor with IC50 of 19 nM for rat Nav1.7, but no inhibition on human, monkey and dog Nav1.7.

Purity: 98.29%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg

Lamotrigine
(LTG; BW430C)
Cat. No.: HY-B0495

Bioactivity: Lamotrigine (BW430C) is a novel anticonvulsant drug for inhibition of 5-HT and sodium channel Target. Sodium Channel Lamotrigine stabilises presynaptic neuronal membranes by blockade of voltage-dependent sodium channels, thus preventing the release of excitatory neurotransmitters, particularly glutamate and aspartate.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g

Lidocaine hydrochloride
(Lignocaine hydrochloride)
Cat. No.: HY-B0185A

Bioactivity: Lidocaine HCl salt, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to the attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 5 g, 10 g

Lidocaine
(Lignocaine)
Cat. No.: HY-B0185

Bioactivity: Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to the attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.

Purity: 99.52%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g

Mexiletine hydrochloride
Cat. No.: HY-A0093

Bioactivity: Mexiletine hydrochloride is a non-selective voltage-gated sodium channel blocker; Class IB anti-arrhythmic compound.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg

Moricizine
(Moracizine)
Cat. No.: HY-B0615

Bioactivity: Moricizine is an antiarrhythmia agent used primarily for ventricular rhythm disturbances.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Mepivacaine hydrochloride
Cat. No.: HY-B0517A

Bioactivity: Mepivacaine is a tertiary amine used as a local anesthetic.

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g

Meticrane
Cat. No.: HY-B0908

Bioactivity: Meticrane is a diuretic. Meticrane inhibits the reabsorption of <b>sodium and chloride</b> ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension.

Purity: 98.79%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg

Myomodulin
Cat. No.: HY-P0268

Bioactivity: Myomodulin is a neuropeptide present in molluscs, insects, and gastropods. Sequence: Pro-Met-Ser-Met-Leu-Arg-Leu-NH2.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nav1.7 inhibitor
Cat. No.: HY-13985

Bioactivity: Nav1.7 inhibitor is a potent Nav1.7 inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Nav1.7-IN-2  
**Bioactivity:** Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

NHE3-IN-1  
**Bioactivity:** NHE3-IN-1 is a sodium/proton exchanger type 3 (NHE-3) inhibitor extracted from patent WO 2011019784 A1.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg, 10 mg

---

Nicainoprol  
**Bioactivity:** Nicainoprol is a fast sodium-channel blocking drug, which is a potent antiarrhythmic agent.

**Purity:** 99.48%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg

---

Oxcarbazepine  
**Bioactivity:** Oxcarbazepine inhibits the binding of [3H]BTX to sodium channels with IC50 of 160 μM and also inhibits the influx of 22Na into rat brain synaptosomes with IC50 about 100 μM.

**Purity:** 99.82%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 5 mg, 20 mg

---

PF 04531083  
**Bioactivity:** PF 04531083 is a selective Na\(_v\)1.8 blocker, and used for the research of neuropathic/inflammatory pain.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 250 mg, 500 mg

---

PF 05089771  
**Bioactivity:** PF 05089771 is a Nav1.7 channel blocker extracted from patent WO/2010/079443 A1, compound example 7B8, has an IC50 of 8.6 nM.

**Purity:** 98.19%  
**Clinical Data:** Phase 2  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

PF-01247324  
**Bioactivity:** PF-01247324 is a selective and orally bioavailable Na\(_v\)1.8 channel blocker with an IC\(_{50}\) of 196 nM for recombinant human Na\(_v\)1.8 channel.

**Purity:** 98.03%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

PF-06869206  
**Bioactivity:** PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC\(_{50}\) of 380 nM.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

---

PH-064  
**Bioactivity:** PH-064 is a sodium channel inhibitor extracted from patent FR 287 9460 A1.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

Phenytoin  
**Bioactivity:** Phenytin is an inactive voltage-gated sodium channel stabilizer.

**Purity:** 99.91%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 1 g, 5 g
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Bioactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin sodium</td>
<td>HY-B0448A</td>
<td>Bioactivity: Phenytoin sodium is an inactive voltage-gated sodium channel stabilizer.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.91%                Clinical Data: Launched Size: 10mM x 1mL in DMSO, 1 g, 5 g</td>
</tr>
<tr>
<td>Propafenone D7 hydrochloride</td>
<td>HY-B0432AS</td>
<td>Bioactivity: Propafenone D7 hydrochloride is the deuterium labeled Propafenone, which is a classic anti-arrhythmic medication.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: &gt;98%                  Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td>Propafenone hydrochloride</td>
<td>HY-B0432A</td>
<td>Bioactivity: Propafenone Hydrochloride is a class of anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.70%                Clinical Data: Launched Size: 10mM x 1mL in DMSO, 1 g, 5 g</td>
</tr>
<tr>
<td>Proparacaine Hydrochloride</td>
<td>HY-66012</td>
<td>Bioactivity: Proparacaine Hydrochloride is a voltage-gated sodium channels antagonist with ED50 of 3.4 mM.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.56%                Clinical Data: Launched Size: 10mM x 1mL in DMSO, 100 mg</td>
</tr>
<tr>
<td>Propoxycaicne hydrochloride</td>
<td>HY-B1243</td>
<td>Bioactivity: Propoxycaicne hydrochloride is the hydrochloride salt form of Propoxyacne, a para-aminobenzoic acid ester with local anesthetic activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.98%                Clinical Data: Launched Size: 10mM x 1mL in DMSO, 50 mg</td>
</tr>
<tr>
<td>Ranolazine</td>
<td>HY-B0280</td>
<td>Bioactivity: Ranolazine is an antianginal medication.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: &gt;98%                  Clinical Data: Launched Size: 100 mg, 200 mg, 500 mg</td>
</tr>
<tr>
<td>Ranolazine dihydrochloride</td>
<td>HY-17401</td>
<td>Bioactivity: Ranolazine(RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.92%                Clinical Data: Launched Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg, 1 g, 5 g</td>
</tr>
<tr>
<td>Riluzole</td>
<td>HY-B0211</td>
<td>Bioactivity: Riluzole hydrochloride is an anticonvulsant drug and belongs to the family of use-dependent Na⁺ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.83%                Clinical Data: Launched Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g</td>
</tr>
<tr>
<td>Riluzole hydrochloride</td>
<td>HY-B0211A</td>
<td>Bioactivity: Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na⁺ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 99.94%                Clinical Data: Launched Size: 10mM x 1mL in Water, 50 mg, 100 mg, 500 mg</td>
</tr>
<tr>
<td>Rimeporide</td>
<td>HY-19273</td>
<td>Bioactivity: Rimeporide is a potent and selective inhibitor of the Na⁺/H⁺ exchanger (NHE-1).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Purity: 98.0%                 Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
</tbody>
</table>

---

www.MedChemExpress.com
Rimeporide hydrochloride
Cat. No.: HY-19273A

Bioactivity: Rimeporide hydrochloride is a potent and selective inhibitor of the Na⁺/H⁺ exchanger (NHE-1).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ropivacaine hydrochloride monohydrate
Cat. No.: HY-80563A

Bioactivity: Ropivacaine HCl is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg

Sodium Channel inhibitor 1
Cat. No.: HY-15736

Bioactivity: Sodium Channel inhibitor 1, one of 3-Oxoisindoline-1-carboxamides, is a novel and selective voltage-gated sodium channel for pain treatment.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Sodium Channel inhibitor 2
Cat. No.: HY-100257

Bioactivity: Sodium Channel inhibitor 2 is a sodium channel blocker extracted from patent WO 2004011439 A2, compound 3c.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Sodium ionophore III (ETH2120)
Cat. No.: HY-101109

Bioactivity: Sodium ionophore III (ETH2120) is a Na⁺ ionophore suitable for the assay of sodium activity in blood, plasma, serum, etc.

Purity: 98.07%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Tenapanor (AZD1722; RDX5791)
Cat. No.: HY-15991

Bioactivity: Tenapanor is an inhibitor of the Na⁺/H⁺ exchanger NHE3 with IC₅₀ values of 5 and 10 nM against human and Rat NHE3, respectively.

Purity: 98.80%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tetracaine (Amethocaine)
Cat. No.: HY-A0079

Bioactivity: Tetracaine is a topical local anesthetic for the eyes; works by interfering with entry of sodium ions into nerve cells.

Purity: 98.03%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g

Triamterene
Cat. No.: HY-80575

Bioactivity: Triamterene blocks epithelial Na⁺ channel (ENaC) in a voltage-dependent manner, which used as a mild diuretic.

Purity: 99.17%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg

Triamterene D5
Cat. No.: HY-80575S

Bioactivity: Triamterene D5 is deuterium labeled Triamterene, which can block epithelial Na⁺ channel (ENaC) in a voltage-dependent manner, which used as a mild diuretic.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Trichlormethiazide
Cat. No.: HY-B0235

Bioactivity: Trichlormethiazide is a thiazide diuretic with properties similar to those of hydrochlorothiazide.

Purity: 98.67%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g
| **Vinpocetine**  
(ethyl apovincaminate) | Cat. No.: HY-13295 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Vinpocetine (Cavinton; Ethyl apovincaminate) is a selective for PDE1 (IC50 = 21 μM)</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.43%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>XEN907</strong></th>
<th>Cat. No.: HY-19958</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>XEN907 is a novel spirooxindole NaV1.7 blocker, inhibits hNaV1.7 with IC50 of 3 nM.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>98.0%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>YM758</strong></th>
<th>Cat. No.: HY-U00309</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>YM758 is a &quot;funny&quot; I sub channel inhibitor.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Zonisamide</strong></th>
<th>Cat. No.: HY-B0124</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.72%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 200 mg, 500 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Zonisamide sodium</strong></th>
<th>Cat. No.: HY-B0124A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Zonisamide sodium is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>200 mg, 500 mg</td>
</tr>
</tbody>
</table>